On May 21, 2025 PharmaMar (MSE:PHM) reported it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide (Press release, PharmaMar, MAY 21, 2025, View Source [SID1234653274]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The MAA submission is based on the statistically significant and clinically meaningfulresults from the pivotal Phase 3 IMforte trial. The data of this study will be shared as an oral presentation "Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the Phase 3 IMforte trial" at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), ASCO (Free ASCO Whitepaper) 2025, on June 2nd.